MedStar Harbor Hospital’s Post

Did you know research published in The Journal of Clinical Psychiatry says, “...women who experience at least two adverse events during their formative years – whether it be abuse, neglect, or some type of family dysfunction– are more than twice as likely to experience depression during perimenopause and menopause as women who either experienced those stressors earlier in life, or not at all”? #2024menopausemakeover #perimenopausepositivity #perimenopausesymptoms #empoweredwomen #menopauseintheworkplace

#EPA2024 has something for everyone … from precision medicine in psychiatry to the importance of managing comorbidities … to harnessing digital enablers … we are proud to work with eMental Health International Collaborative (eMHIC) to explore e-Mental Health opportunities to improve outcomes:

People living with #schizophrenia and their care partners have long carried the burden of this mental health condition, which impacts how a person thinks, feels and behaves, and is often disabling. As we reenter psychiatry, we remain steadfast in our commitment to advancing our pipeline of potential medicines for neurological conditions to address unmet needs for patients. Learn more about the interim long-term safety and metabolic outcomes data from the Phase 3 EMERGENT program in adults living with schizophrenia shared today at #SIRS2024: https://bit.ly/3xrjjf8

Exciting advancements in mental health research! A recent study from the Spanish Journal of Psychiatry and Mental Health on reproductive outcomes for women with schizophrenia challenges stereotypes and highlights the importance of proactive care. This resonates with companies like Reviva, finishing up it’s Phase 3 trial on schizophrenia, paving the way in CNS treatments. Its success with RP5063 in a Phase 3 trial for schizophrenia treatment is a beacon of hope. Breaking barriers, improving lives! Learn more and read our disclosures - https://ow.ly/BPox50Qc7KS #MentalHealthMatters #InnovationInHealth #RevivaPharma

Good news was recently announced by UCLA Health about the benefits of #TMS! Researchers showed not only its effectiveness, but also that it may work even more rapidly than past findings have suggested. The new study published in Psychiatry Research found that 54% of patients exhibited clinical response (at least a 50% improvement) in mood symptoms when examined using multiple depression rating scales. “What we're seeing in our analysis of our large data set is that a majority of patients get significantly better. What’s most exciting to see is that these patients generally start reporting improvement within a week of starting treatment, even though the treatment itself continues for several weeks to build the full benefit," stated one of the researchers. Learn more: https://bit.ly/47ELc0h #DeepTMS #depression #anxiousdepression #mentalhealth #mentalhealthawareness

Look how easy DeepCura can automate a custom Psychiatry note in this short video. Same principle apply to any other specialty.

In case you missed it, Dr. Kate Kresge, Head of Medical Education at Rupa Health, recently hosted a webinar for the Psychiatry Redefined community on Maximizing Efficiency & Patient Care. The recording is now available, and you can watch for free by following the link provided here! https://lnkd.in/eUcdFQm2 #precisionmedicine #professionaldevelopment #functionalmedicine #testingprotocols #integrativemedicine

New hope for our Veterans! A groundbreaking study published in the Journal of Clinical Psychiatry sheds light on the effectiveness of IV ketamine treatment for Veterans battling treatment-resistant depression. 215 Veterans received six IV ketamine infusions, resulting in significant symptom relief. 👉 Key Findings: -Nearly half of the Veterans experienced a meaningful drop in depression scores. -One-third saw their depression scores halved. -Fifteen percent achieved remission from depression. Lead researcher Paul Pfeiffer underscores that while ketamine isn’t a “silver bullet,” its impact on previously treatment-resistant cases is remarkable. With ongoing studies exploring ketamine’s compatibility with other therapies, the future of treatment-resistant depression looks promising. Study 👉 https://lnkd.in/grhvka-3 #MentalHealth #KetamineResearch #DepressionRelief #VeteranAffairs #PTSD #Depression #IVKetamine #KetamineTherapy

How clinicians should consider approaching premenstrual dysphoric disorder (PMDD) “This is the best psychiatry webinar I have ever watched.” – General Practitioner The course ‘Integrative Perspectives on Women’s Mental Health: PMDD and Menopausal Depression’ focuses on the clinical features, pathogenesis, and treatment strategies of menopause and perimenopause. Visit The Academy to learn more: https://lnkd.in/gmHXHfXv

Our researchers are rethinking dementia diagnosis. 🧠💡   We often hear about memory loss as a common symptom of dementia, but there's a crucial aspect that deserves more attention. Researchers from CHeBA and the The MARCS Institute for Brain, Behaviour and Development at Western Sydney University are shedding light on this often overlooked issue.   In their perspective paper published in "Frontiers of Psychiatry," these experts highlight the significance of assessing emotional responses in individuals with dementia to enhance the diagnosis and management of the condition.   🔗Read more https://bit.ly/3FEnS6B UNSW Anjani Meka Joyce Siette #dementia #brainhealth #dementiaresearch #healthyageing #mentalhealth #CHeBA